DVAX vs. ALKS, IONS, FOLD, LGND, BCRX, MNKD, CLDX, NVAX, OPK, and GERN
Should you be buying Dynavax Technologies stock or one of its competitors? The main competitors of Dynavax Technologies include Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Celldex Therapeutics (CLDX), Novavax (NVAX), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry.
Dynavax Technologies vs.
Alkermes (NASDAQ:ALKS) and Dynavax Technologies (NASDAQ:DVAX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.
Alkermes has higher revenue and earnings than Dynavax Technologies. Alkermes is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks.
Alkermes received 225 more outperform votes than Dynavax Technologies when rated by MarketBeat users. Likewise, 70.38% of users gave Alkermes an outperform vote while only 65.93% of users gave Dynavax Technologies an outperform vote.
95.2% of Alkermes shares are held by institutional investors. Comparatively, 97.0% of Dynavax Technologies shares are held by institutional investors. 4.9% of Alkermes shares are held by insiders. Comparatively, 3.0% of Dynavax Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Alkermes has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Dynavax Technologies has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.
Alkermes has a net margin of 23.57% compared to Dynavax Technologies' net margin of 9.85%. Alkermes' return on equity of 30.80% beat Dynavax Technologies' return on equity.
Alkermes currently has a consensus target price of $38.46, indicating a potential upside of 10.55%. Dynavax Technologies has a consensus target price of $21.50, indicating a potential upside of 55.35%. Given Dynavax Technologies' higher probable upside, analysts clearly believe Dynavax Technologies is more favorable than Alkermes.
In the previous week, Alkermes had 12 more articles in the media than Dynavax Technologies. MarketBeat recorded 16 mentions for Alkermes and 4 mentions for Dynavax Technologies. Dynavax Technologies' average media sentiment score of 1.54 beat Alkermes' score of 1.22 indicating that Dynavax Technologies is being referred to more favorably in the news media.
Summary
Alkermes beats Dynavax Technologies on 12 of the 18 factors compared between the two stocks.
Get Dynavax Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dynavax Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:DVAX) was last updated on 3/25/2025 by MarketBeat.com Staff
